At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Detoxification From the Lipid Tract by Cocktail Design
In Brief
A Phase 4 clinical trial evaluating electroencephalogram biofeedback, electrical brain stimulation, and 8 other interventions for COVID-19 Vaccine Adverse Reaction. Completed, enrolled 1 participant across 1 site.
Detailed Summary
Apart from electroencephalogram biofeedback and electrical brain stimulation adopted for maintenance treatment, the study utilizes ultra-low frequency transcranial magnetic stimulation (ULF-TMS) for initial γ-aminobutyric acid (GABA) stimulation. The cocktail therapy starts after the primary efficacy endpoint, and concomitant therapy is adopted throughout the study.
Study Details
Timeline
Interventions
EB is conducted for 20 minutes per section with two sections per day in the primary efficacy endpoint.
EBS is conducted for 20 minutes per section per day in the primary efficacy endpoint.
ULF-TMS is conducted mainly for the left side of the participant's brain for 20 minutes per section per day in the primary efficacy endpoint.
Sertraline is taken in the morning for 150 mg per day.
Clonazepam is taken in the morning for 1 mg per day.
Alprazolam is introduced near the end of the primary efficacy endpoint for 0.4 mg per night.
Metoprolol is introduced at the secondary efficacy endpoint starting with 47.5 mg per night and increase to 95 mg per night.
Olanzapine is taken throughout the trial with 7.5 mg per night at first, and increases to 10 mg per night after the cocktail therapy.
Pravastatin sodium is introduced in the secondary efficacy endpoint with 20 mg per night.
Sacubitril valsartan sodium is introduced in the secondary efficacy endpoint with 100 mg per day.